Differential Gonadotropin Secretion: Blockade of Periovulatory LH but Not FSH Secretion by a Potent LHRH Antagonist

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The dependence of periovulatory gonadotropin secretion on LHRH was assessed with the use of a potent LHRH antagonist [ALHRH; (Nac-L-Ala1, p-Cl-D-Phe2, D-Trp3,6) LHRH]. Blood samples were collected hourly from 14.00 h proestrus (P) through 09.00 h estrus (E) from intact cycling female rats. ALHRH was administered at 09.00 or 13.00 h Pbefore the proestrous increases in gonadotropins had commenced or at 23.00 h P after the LH and primary FSH surges had occurred but preceding the secondary FSH surge. Antagonist given at 09.00 or 13.00 h P completely blocked the LH release with levels remaining undetectable in most animals (<30 ng/ml) throughout the sampling period. However, administration of antagonist at these times failed to block completely the primary FSH surge although peak values were reduced when compared with controls, which displayed normal gonadotropin surges. In addition, ALHRH administered at 23.00 h failed to alter the magnitude or other characteristics of the secondary FSH surge when compared with controls.

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEN

Journal ID (nlm-ta): Neuroendocrinology

Journal ID (doi): 10.1159/issn.0028-3835

Title: Neuroendocrinology

Publisher: S. Karger AG

ISSN (Print): 0028-3835

ISSN (Electronic): 1423-0194

Publication date Subscription-year: 1984

Publication date (Print): 1984

Publication date (Electronic): 28 March 2008

Volume: 38

Issue: 5

Pages: 357-361

Affiliations

^aDepartment of Anatomy and Laboratory of Neuroendocrinology, Brain Research Institute, UCLA School of Medicine, Los Angeles, Calif.; ^bDepartment of Medicine, Harbor-UCLA Medical Center, Torrance, Calif.; ^cDepartment of Biochemistry, University of Colorado Medical School, Denver, Colo., USA

Article

Publisher ID: 123917 Other ID: Neuroendocrinology 1984;38:357–361

DOI: 10.1159/000123917

PubMed ID: 6427646

SO-VID: 2a7a3ba5-2a87-45e0-bcd4-876af2f374ec

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 05 January 1983

Date accepted : 13 October 1983

Page count

Pages: 5

Comments

Comment on this article

scite_